Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

OBJECTIVES: To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS). METHODS: A total of 159 patients with biological-naïve AS, with active disease (Bath Ankylosing S...

Descripción completa

Detalles Bibliográficos
Autores principales: Baeten, Dominique, Østergaard, Mikkel, Wei, James Cheng-Chung, Sieper, Joachim, Järvinen, Pentti, Tam, Lai-Shan, Salvarani, Carlo, Kim, Tae-Hwan, Solinger, Alan, Datsenko, Yakov, Pamulapati, Chandrasena, Visvanathan, Sudha, Hall, David B, Aslanyan, Stella, Scholl, Paul, Padula, Steven J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104676/
https://www.ncbi.nlm.nih.gov/pubmed/29945918
http://dx.doi.org/10.1136/annrheumdis-2018-213328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104676/
https://www.ncbi.nlm.nih.gov/pubmed/29945918
http://dx.doi.org/10.1136/annrheumdis-2018-213328

Ejemplares similares